On March 30, 2012, Roche announced results of a phase III trial of its antibody conjugate, trastuzumab emtansine (T-DM1), in the treatment of HER2-positive metastatic breast cancer patients that had previously received HERCEPTIN and a taxane-based chemotherapy. The study showed significantly longer progression-free survival compared to the group receiving lapatinib and capecitabine. Final overall survival results were not yet mature.
Based on these findings, Roche anticipates submitting applications for regulatory approval in Europe and in the U.S. later this year.
Roche’s press release may be found here.